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REVIEW
An overview of the time trade-off method: concept, foundation, and the evaluation 
of distorting factors in putting a value on health
Anna K. Lugnéra and Paul F.M. Krabbeb
aTheta Research, Zeist, The Netherlands; bDepartment of Epidemiology, University of Groningen, University Medical Center Groningen, Groningen, 
The Netherlands
ABSTRACT
Introduction: Preference-based instruments measuring health status express the value of specific 
health states in a single number. One method used is time trade-off (TTO). Health-status values are 
key elements in calculating quality-adjusted life years (QALYs) and are pertinent for resource allocation. 
Since they are used in economic evaluations of healthcare, searching for a theoretical foundation of TTO 
in economics is justified.
Area covered: This paper provides an overview of TTO, including its relation to economic theory, and 
discusses biases and distortions, compiled from recent and older research. Inconsistencies between TTO 
and random utility theory were detected; The TTO is confounded by time preferences and by respon-
dents’ life expectancies. TTO is cognitively challenging, therefore guidance during the interviews is 
needed, producing interview effects. TTO does not measure one thing at a time, nor are the values 
independent of other states that are being valued in the same task. That is, TTO does not exhibit 
theoretical measurement properties such as unidimensionality and the invariance principle.
Expert opinion: We conclude that the TTO may be a pragmatic method of eliciting health state values, 
but the limitations in regard to measurement theory and practical elicitation problems makes it prone 
to inconsistencies and arbitrariness.
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It is generally acknowledged that apart from life years or 
survival, the ‘quality of life’ is crucial to any health evaluation. 
Since the introduction of the concept of the quality-adjusted 
life year (QALY), many attempts have been made to define 
quality-of-life and health. Since the ideas differ of what defines 
health and what exactly is being measured in its evaluation, 
the definition of quality-of-life remains elusive. In the litera-
ture, the term quality-of-life is used interchangeably with sub-
jective health status, perceived health status, health-related 
quality of life, and general well-being [1–4]. If psycho-social 
and social functioning are included, the concept is often 
referred to as HRQoL (health-related quality of life). The criteria 
for quality-of-life are largely subjective, as opposed to stan-
dard health indicators such as survival, serum cholesterol 
levels, and bone mineral density. We use the term health 
status and acknowledge that this subjective phenomenon 
requires specific methods to be measured.
Health outcome instruments that measure health status can be 
developed within various measurement frameworks, e.g. indicat-
ing the frequency, intensity, or level of a specific health domain 
(e.g. mobility, pain) [5]. However, when comparing health out-
comes across different populations, conducting disease modeling 
studies, and performing economic evaluations of various health-
care interventions, preference-based instruments are more useful. 
Preference-based measures expresses preferences in a single 
numeric metric (which we refer to as a ‘value’ of a particular health 
state), and so, these measures incorporate weights that reflect the 
importance attached to a set of specific health aspects. Therefore, 
preference-based measures reflect the overall quality of an indivi-
dual patient’s (perceived) health status.
One of the prevalent preference-based methods to derive 
a value of a health state is time trade-off (TTO). The wide-
spread use of the EQ-5D instrument, in which the value sets 
are mainly derived from TTO [6], has certainly contributed to 
the extensive use of TTO to construct value sets for health 
states. The AQol-8D and its predecessors (4D, 6D and 7D 
versions) developed in Australia are other instruments that 
are largely based on TTO values [7]. The EQ-5D is commonly 
recommended for use in health economic evaluations of 
healthcare as a basis for resource allocation [8].
In the area of clinical decision-making, individual patients are 
often involved in eliciting values for health states that concern 
possible outcomes related to their own disease and optional 
treatment modalities. We refrain from incorporating such TTO 
values in our review because clinical decision-making is an entirely 
different area of research, with different goals and different pre-
mises [9]. TTO is also often used as a stand-alone method to value 
health state for a specific disease. In this overview, we specifically 
deal with the more general use (economic evaluation) of TTO were 
values for a (large) set of health states are derived from a (large) 
sample of respondents from the general population.
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Through the years a large amount of literature has accumu-
lated that discusses the merits and shortcomings of TTO, both on 
theoretical and empirical grounds. This overview provides insight 
into its development, including its relation to economic theory, 
and discusses the biases and distortions of the method. To put 
the TTO into its historical context that would explain the broad 
use of the method, we start with a brief overview of the QALY as 
a summary measure of health and preference-based measure-
ment. Problems associated with the TTO are then summed up 
and discussed from the perspective of economic reasoning, and 
in light of the empirical evidence of its validity.
2. Quality-adjusted life years
In the early 1970s Fanshel and Bush introduced the QALY 
concept, at the time called ‘function years’, in a paper evalu-
ating a tuberculin skin-testing program [10]. The QALY con-
cept is a descriptive summary measure where the two main 
components of health – mortality and morbidity (i.e. health 
status) – are combined. Most of the methodological aspects 
pertinent to the measurement of health are discussed in that 
paper [10], and, although there has been some variation in the 
terminology used these aspects are still valid. The concepts of 
the index day and health day were mentioned by Torrance 
and colleagues in 1971 and ’72 [11,12]. Also, Grogono and 
Woodgate (1971) published an approach to measure health 
[13]. In their approach, ten domains specified health and with 
a simple weighting procedure they produced ‘health-years’. 
A few years before, Klarman and colleagues (1968) [14] com-
pared treating options for chronic renal disease, measured as 
life years gained. By means of arbitrary adjustments in their 
epidemiological cohort model analyzes of ‘quality of life’ were 
performed. The term ‘quality-adjusted life year’ was intro-
duced in 1976 by Zeckhauser and Shepard [15].
The quality-adjustment factor in the QALY requires 
a numeric metric with an upper bound of 1.0 corresponding 
to full health, with poorer health states being arrayed along 
a single-dimensioned continuum at scale values less than 1.0. 
Being dead has a value of 0.0 on this scale [16]. Various terms 
are used to refer to this quality metric such as value, utility, 
strength of preference, or index.
3. Preference-based measurement
Preference-based methods of valuation or measurement such 
as standard gamble (SG) and TTO (see next section) capture 
the overall health condition of individuals and reflect the value 
of a health state. The core of a preference-based measurement 
framework consists of a response task comparing at least two 
objects with the objective of expressing which object is pre-
ferred (is better). These objects can be different health states 
or health states with different duration, or the objects can be 
the risk of dying or full recovery. A health state is often 
described as a small set of attributes, whereby each attribute 
entails a limited number of levels of severity. The respondents 
score the set of attributes as a whole, and not the individual 
attributes separately. In doing this, the ability to read and 
mentally processing all of the attributes simultaneously is 
required [17]. In comparing complete attribute sets, which 
differ according to levels of severity (i.e. the health state), 
a preference for one health states is evoked. Health states 
can also be compared with a specified health outcome (e.g. 
immediate death or living in full health for a specified number 
of years). People’s choices are then assumed to be based on 
trading off one health state (with specific levels of severity) 
against another health state, with other levels of severity or 
health outcomes. In short, preference-based methods come 
down to teasing out the ‘true’ values that people assign to 
specific health states.
Parallel to the development of the QALY concept, the 
development of preference-based methods in health econom-
ics started in the 1970s, both in North America [12,18–20] and 
in the UK [21]. Different preference-based methods to derive 
values trace their ancestry to different scientific fields, thereby 
entailing their own specific methodological consequences and 
different applications. Preference-based methods have been 
introduced from decision science [11], health economics [22– 
24], marketing [25], psychometrics [26], public health [27], and 
clinimetrics [28]. Which method should be used to derive 
health-state values is still under debate, however [29,30].
4. Standard gamble and game theory
The first theory on how to assign a numeric metric to utility 
was worked out by means of game theory [31,32]. Before this 
breakthrough, preferences were expressed as rankings with-
out a cardinal or ratio measurement level (metric) implied. The 
renowned theory of expected utility is an axiomatic theory of 
rational choice under uncertainty. Individual behavior may be 
characterized as if choices were being made to maximize the 
expected utility. When the choices (i.e. preferences) obey the 
axioms of completeness and transitivity, the utility of different 
alternatives can be calculated [33].
The method of eliciting utilities as described by the von 
Neumann and Morgenstern (vNM) theory has become known 
as the standard gamble (SG). The introduction of SG is hard to 
trace, but it is clear that it was neither mentioned nor devel-
oped by vNM. Rather, it is based on Thurstone’s much earlier 
concept of probabilistic preferences [34–37]. In SG, a rational 
individual would choose the one lottery with the highest 
expected outcome [38]. In the original vNM theory this out-
come was monetary, ‘supposed to be unrestrictedly divisible 
and substitutable, freely transferable and identical, even in the 
quantitative sense … ’ [31, p.8].
Article highlights 
● Methods that are less biased than the time-trade off are needed to 
derive values and utilities for health.
● The research paradigm of health economics that underpins present 
protocols to value health states has too many flaws to adequately 
quantify a subjective phenomenon such as health.
HRQOL values in cost-effectiveness studies (e.g. QALYs) are more 
valid if based on patient-reported and patient-centered values.   
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Expected utility theory uses monetary outcomes, since ‘the 
aim of all participants in the economic system, consumers as 
well as entrepreneurs, is money, or equivalently a single mone-
tary commodity’ [31, p.8]. Preferences (utility) of goods are 
often expressed as the amount of money people are willing 
to pay. By replacing money as an outcome, SG has been used 
to elicit the utility of a health state or health intervention. One 
of the earliest published applications of SG in the context of 
deriving utilities for specific health states involved an experi-
ment where two physicians would draw imaginary pills out of 
a box that would cure their patient, but with a risk of drawing 
a pill that would kill the patient [39]. Similar methods were used 
in clinical or patient decision making, whereby individual 
patients performed tasks to derive values for specific possible 
treatment outcomes [40,41]. In the setting of economic evalua-
tion, the valuation procedure is often different; a wide range of 
hypothetical general health states, in contrast to disease- 
specific states, are assessed with a preference-based method. 
Whether existential outcomes such as health also can be cap-
tured by this approach is not clear. In the SG method the object 
of interest seems to have been transposed into a normative 
framework of valuation that may be a reliable approach to 
quantify normal goods, such as cars and holidays, but may be 
less appropriate to deal with the valuation of health [42]. 
Furthermore, unlike money, health cannot be transferred from 
one individual to another, which makes it different from other 
commodities (goods), making the transformation from SG to 
health status utilities cumbersome.
5. Time trade-off
5.1. Foundation
Due to the cognitive difficulties with the appraisal and proces-
sing of probabilities, which is necessary in the SG, as recognized 
by Torrance and colleagues in 1972, the TTO was developed for 
the specific application of valuing health states [12]. In his 
dissertation (1971), Torrance states that the SG and TTO meth-
ods give ‘equivalent and reliable results but the time trade-off 
method was found easier to administer’ [11, p. 125]. Torrance 
also refers to communication with Bush, proving his awareness 
of work in other research groups [11, p.33]. Bush and colleague 
Fanshel discussed the basic approach of TTO in 1970, referring 
to the notion as ‘weighting through equivalence in time’ [10, 
p.1043]. For Torrance the TTO was a ‘short-cut’ method of 
obtaining values equivalent to those estimated using SG 
(which was theoretically sound according to the vNM utility 
theory). TTO values were not intended to be used directly, nor 
was the method meant to replace SG entirely. The purpose of 
TTO was to estimate a functional relationship between SG and 
TTO values to interpolate TTO values between utilities esti-
mated using SG. Interestingly, Torrance introduced TTO but 
did not use it for his later work (HUI-2, HUI-3). There does not 
seem to be consensus on whether the two methods (SG and 
TTO) give similar values [43] or not [44].
One reason for the popularity of TTO is that it is a preference- 
based method with a format and operationalization procedure 
that has a connection to economic reasoning (e.g. trade-off: 
sacrifice one alternative in order to receive another). 
Furthermore, TTO prompts face validity as it mimics the QALY 
concept and resonates with the medical context [43]. Notably, 
the values deduced by TTO are often referred to as utilities, but 
TTO does not conform to the expected utility theory in the sense 
that there is no element of risk involved in the assessment. As 
such, some researchers claim that formally TTO tasks produce 
values, and not utilities.
The wide use of the TTO in economics evaluations has 
prompted efforts to find a theoretical foundation of TTO in 
economics. The starting point in economics is that there are 
unlimited human wants which are to be met by limited 
resources. Essentially, this is what economists call scarcity, 
and it is closely related to people’s choices for goods and 
services. When an individual is faced with a number of alter-
native options to choose from, he will choose the one that he 
prefers. This is equivalent to choosing the option that gives an 
individual the highest utility, i.e. what gives an individual the 
highest benefit, what makes him or her feel better. Under 
conditions of scarcity, the choice is a trade-off that involves 
giving up one commodity in return for gaining another one.
5.2. Valuation task
In a TTO valuation task the respondents are asked to trade off 
duration of life against health status. The trade-off entails choos-
ing a shorter life spent in full health or living longer but in 
a lesser state of health. Often this is done by using an iterative 
process to offer the respondent different lengths of life before 
they indicate indifference. Intuitively, individuals would prefer to 
spend a shorter time in full health than a longer time in a lesser 
health state, and therefore they would trade off life years for 
better health. The number of years sacrificed in full health 
represents the value of the lesser state.
In the operationalization of TTO, as applied in the 
Measurement and Valuation of Health Study (MVH) [45], the 
first, large population study using TTO, the preferences are 
elicited by confronting a respondent with a suboptimal health 
state of a given duration (x, often 10 years). As the competing 
alternative, a better health state (conventionally perfect health) 
is offered but with a shorter duration (y < 10). In the TTO 
exercise, the 10-year period is conventionally followed by 
death. The respondent is asked to state the duration spent in 
perfect health (y) at which he/she is indifferent between the 
duration y and the 10 years in the lesser health state. The value 
of the lesser state can then be established as y/10 (Figure 1).
5.3. Position of dead
TTO was originally developed to assess values for states con-
sidered better than being dead [46,47]. An important devel-
opment of TTO was the elaboration by Torrance in 1984 of the 
method to accommodate states regarded as worse than being 
dead [48]. An important claim often made is that health states 
must be valued on a scale where the value of being dead is 
0.0, because the absence of life is considered equivalent to 
zero QALYs [12,43]. Inevitably this rule leads to assigning 
negative values for very bad health states.
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The MVH study used a specific methodology for worse-than 
-dead states. First, respondents were asked if a state is 
regarded as better or worse than dead. If worse, the respon-
dent is asked how many years (t) spent in that state followed 
by a period of perfect health, summing to 10 years, would be 
equivalent to immediate death. In an iterative process t is 
decided upon. Assigning the values 0 and 1 to being dead 
and full health, respectively, the valuation for the worse-than- 
dead state is 1-(10/t). This follows from the calculation that the 
time spent (t) in the state plus the remaining time spent in full 
health (10-t) would add up to 0. This implies that the value for 
a worse-than-dead state theoretically falls in the inter-
val (–∞, 0).
In lead-time TTO (see also below), values for all states can 
be elicited in one procedure, avoiding the need to engage in 
a different procedure for states worse than dead [22,23]. The 
composite TTO, with its lead-time TTO part for the states 
worse than dead, may solve some of the problems. However, 
the main problem with the original TTO has not been 
resolved, namely that different procedures were used for 
states worse and better than dead [49].
5.4. Alternative TTO versions
Alternative versions of TTO have been developed in an effort 
to optimize the method for producing more credible values or 
to deal with temporary health states [50]. In particular such 
efforts have been undertaken for the EQ-5D instrument. 
Recent developments around the introduction and valuation 
of the EQ-5D-5 L (with 5 levels instead of 3) instrument still 
rely on TTO, but in a slightly different form [51]. Adjustments 
in the TTO procedure concern states worse than dead. Valuing 
health states with the lead-time TTO involves imagining 
a period of time in full health before the respondent moves 
into a state of less than full health (Figure 2). In contrast to 
lead-time TTO, lag-time TTO involves imagining a health state 
that is less than full health, starts immediately, and is followed 
by a lag-time of good health. Lag-time TTO produced lower 
values than lead-time TTO, and the difference increased in 
longer time frames [52]. The most recent EuroQol TTO version 
combines a conventional TTO to elicit values for states 
regarded better than dead and a lead-time TTO variant for 
states worse than dead; it is referred to as composite TTO [24]. 
Unfortunately, valuation studies based on the composite TTO 
showed almost no discrimination among values for states 
worse than dead [53].
6. Time trade-off distortions
6.1. Theory
There have been some attempts to fit the TTO into the eco-
nomic utility theoretical framework [54,55]. In those investiga-
tions, the axioms of rational preferences are assumed to hold. 
Yet, experiments and tests for specific conditions and 
Figure 1. Representation of the time trade-off (TTO) methodology as performed in the MVH study. The iterative procedure to arrive at the point (number of years) 
where a respondent is indifferent between a shorter life in full health, State A (dark green), and 10 years in a lesser health state, State B (light blue) is illustrated with 
the arrows. For states perceived as worse than dead by the respondent, the time spent in that state is followed by some time in full health. The iteration regards the 
number of years in full health that are needed to compensate for the years spent in a state worse than dead.
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properties give extensive empirical evidence of choices made 
by individuals that are inconsistent with the underlying theory 
of rational individuals [56–61].
Most inconsistencies between TTO and expected utility 
theory have been found when examining the possible influ-
ence of duration. The assumption of constant proportional 
trade-offs entails that the proportion of remaining life span 
that one would trade for a specified improvement in quality is 
independent of the remaining duration of life (e.g. TTO). There 
is mixed evidence of whether this assumption holds [61,62]. 
Another assumption is utility independence. Lack of utility 
independence is undermining the results of TTO; its absence 
means that the value of the health state depends on the time 
spent in it [62]. The lack of utility independence also implies 
that the value given in the valuation task depends on the 
order of the states presented in the task [47]. Overall, there 
is substantial empirical evidence that an individual’s choice 
behavior does not align with the assumptions of economic 
utility theory [63–67]. Many of these violations of the axioms 




In the first application of TTO, the values referred to a kidney- 
dialysis regime, and one of the conclusions was that the value 
of a health state depends on the amount of time spent in it 
[12]. Subsequently, the authors stressed the importance of 
carefully determining the duration of the state before measur-
ing its value, and they emphasized the need to control dura-
tion during the measurement process. Through the years, 
more evidence has been gathered showing that duration 
affects the values measured [68–72]. TTO is not only con-
founded by time preferences and the framing effect due to 
the chosen duration; it is also confounded by the respondents’ 
different life expectancies [73–76]. Attempts have more 
recently been made to explore and test these time duration 
effects [77], some based on the well-know and interesting 
prospect theory [78]. This theory explains that valuations in 
a TTO task differ depending on the respondents’ own per-
ceived life expectancy (which can be longer or shorter than 
the standard 10 years in TTO). However, hands-on methods to 
correct or adjust TTO values based on findings of prospect 
theory are yet unavailable and will likely complicate TTO 
assessments even further.
6.2.2. Indifference procedure
Economics, as a discipline, has a tradition of assuming ration-
ality and acting on the basis of perfect information. This 
tradition is reflected in the implicit assumption that the 
response received from a respondent will precisely reflect 
a considered choice or valuation for a specific outcome [33]. 
Regarding valuations, respondents may arrive at this response 
in one step. In practice, however, valuing health states with 
TTO is done through an iterative procedure to make the task 
more manageable.
The quarter-year increments used in the MVH protocol 
resulted in a large number of health-state predictions having 
negative average values (the lowest possible value is −39) 
[6,79]. In the EuroQol Valuation Technology (EQ-VT) protocol for 
the EQ-5D-5 L [51,80], which is based on a computer-assisted 
personal interview mode, the iterative process produces an 
accumulation of indifferences in three specific iteration steps, 
leading to a large number of valuations of −1.0, 0.0, and 1.0 for 
different states [81,82]. Where the participants’ responses indi-
cate a value of −1.0, we know their value is at most −1.0, since 
that observation is censored. This suggests that using these 
individual values to compute average values needs to take 
account of this censoring in some way [83,84]. The EQ-5D-5 L 
value set derived in England, reports that respondents were 
more likely to value a state at 0.0, 0.5, or 1.0 rather than any 
intermediate number, and there were very few values in the 
range of −0.5 to 0.0 [52]. These discontinuities suggest that the 
participants were providing quite crude responses. Indeed, parti-
cipants who valued all health states using either a single high 
value (such as 1.0) or a single low value (such as 0.0), are possibly 
giving a signal that the states are either ‘good’ or ‘bad’ rather 
than providing numbers that have cardinal meaning. It cannot 
be denied that the iteration steps influence the values, but the 
exact size of the influence can hardly be defined.
6.3. External distortions
6.3.1. Cognitive understanding
An important empirical concern is the extent to which respon-
dents understand and respond accurately to the judgmental 
tasks of the TTO (Figure 3). Qualitative research has shown 
that respondents often have difficulty distinguishing between 
Figure 2. In the new EQ-VT protocol, lead-time TTO is used for states worse than dead. Here the respondent needs to picture a life in full health for 10 years before 
ending up in the state worse than dead for 10 years. . Maximally 10 years of life can be sacrificed to arrive at the point where the x years in full health are equivalent 
to a life of 10 years in full health followed by 10 years in a state worse than dead.
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the health states to be valued, understanding the hypothetical 
nature of health states, and conceptualizing being dead; the 
research also points out that the respondents may have their 
own religious or spiritual beliefs about being dead [85–87]. 
These cognitive distortions include those relating to the fram-
ing of issues, anchoring, time inconsistency, making choices in 
the presence of uncertainty (what will be happening after the 
10/20 years of the TTO representation?), overconfidence, and 
many others [88–90].
6.3.2. Interviewer effect
Experience shows that the assessment of TTO requires the 
presence of a trained interviewer and/or specialized computer 
programs. The current EQ-VT TTO protocol dictates trained 
interviewer assistance. Respondents are now confronted with 
complex and strenuous instructions offered by the inter-
viewer, on top of the already complex representation (the 
health profile bars, written instructions, health-state descrip-
tions). Acknowledging these difficulties, solutions were sought 
by the EuroQol Group in quality control tools to enhance 
protocol compliance to reduce interviewer effects. These 
tools are based on continuous data monitoring and various 
checks during data collection [91]. Nevertheless, recent studies 
have made it clear that trained interviewers do not seem to 
explain the tasks in the same structured way. This leads to 
interviewer-dependent values [92,93]. Such interviewer effects 
have also been traced in the MVH study for the VAS values 
[94]. Figure 4 sums up some of the issues discussed in this 
paragraph.
7. Conclusion
In this paper TTO is discussed as a method to derive values for 
health states. Because the method was developed in connec-
tion to the framework of expected utility theory and is an 
adaptation of the SG method of measuring utility, the values 
elicited with TTO would supposedly obey the axioms of eco-
nomic theory. However, the research described in the litera-
ture shows that this is not the case. Compelling arguments 
against using TTO have been raised by several authors, most 
of them health economists themselves. In fact, TTO seems to 
be associated with many problems, both theoretical (e.g. axio-
matic violations, problems in dealing with states worse than 
dead, time preference) and practical (e.g. difficult for people to 
perform, trained interviewer assistance required). From 
a measurement perspective, TTO has been criticized for its 
susceptibility to framing issues (e.g. duration of the time 
frame, mode of administration, indifference procedure). The 
TTO method is a rather pragmatic approach to arrive at values 
for health states, but methodological, procedural, and 
Figure 3. TTO instruction as used in the EQ-5D-5 L valuation protocol.
Figure 4. Issues that influence the values elicited by the TTO, selected references.
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analytical problems are prominent in the applications of TTO 
[95]. We believe that what is needed for the measurement of 
a subjective phenomenon such as people’s perceived health 
status is a simpler and theoretical underpinned measurement 
model.
8. Expert opinion
TTO is cognitively challenging. As a result, there is a need for 
guidance during interviews, which in turn produces interview 
effects. The presence of significant interviewer effects [52] gives 
reason to doubt the straightforward interpretation of valuation 
data as ‘true’ representations of individuals’ values of health 
states. There are reasons to suspect that many of those partici-
pating in TTO valuation tasks do not understand the tasks, are 
not fully engaging with the tasks at hand, or simply want to 
finish the valuation exercise as quickly as possible. All of these 
factors might have serious effects on the generated values. 
Furthermore, valuations provided by those who do understand 
and are engaged are influenced by the framing of the tasks and 
the interviewer’s approach [96]. The need to introduce quality 
control on collected values during TTO valuation studies, and 
drop specific responses, indicates that the TTO cannot be con-
sidered a robust measurement method.
The combination of health-state descriptions augmented 
with the duration of these states has introduced biases and 
distortions into the health state values due to the time element. 
This is due to various factors: time preference, duration may 
become a dominant attribute, life stage concerns, violation of 
constant proportional time trade-off, and maximal endurable 
time [52,74,97–99]. One solution that has been suggested is to 
harmonize TTO methods [49]. A method of correcting for time 
preference in the analysis of TTO data has been suggested [100] 
but seldom used [101]. Moreover, although standardizing may 
seem an attractive solution, it will only treat the symptoms. In 
the case of the EQ-5D-5L, a discussion is started, challenging its 
leading use [102]. The recent extension of this instrument has 
even led to an in-depth investigation by the UK government 
[103]. An official report commissioned by NICE and the 
Department of Health and Social Care addresses several con-
cerns related to the UK-values estimated for the 5-level version 
of the EQ-5D [104]. Many of these concerns seems associated to 
the principal valuation technique used, the TTO. Yet, these 
results may be typical for the UK EQ-5D-5 L valuation study, 
as in other countries that used later versions of the EQ-VT 
protocol, the TTO exercise produced results that were more 
balanced with smaller interviewer effects.
The current convention in QALY computation is that the 
lower anchor on the scale should be 0.0 and is defined as 
a state equivalent to being dead [105]. The argument for 
anchoring dead and not for the worst health state on 0.0, is 
because the absence of life is considered equivalent to zero 
QALYs [12,43]. Recently, a discussion has started whether 
positioning dead as zero is a theoretically requirement in the 
QALY approach [106]. These authors show that the arguments 
for dead as a zero anchor are not very strong. Yet, the exis-
tential notion ‘dead’ remains commonplace as the anchoring 
label in QALY computations and therefore the use of TTO.
To some extent it is understandable that valuation methods 
such as the TTO include dead since it is a natural part of the life 
course (the end of it), and therefore it may be intuitive to use 
‘dead’ as the lowest point on the scale to express the quality of 
health (and even life). As a consequence, health states consid-
ered as ‘worse than dead’ have to be quantified or assessed one 
way or the other. Inevitably, this means that very bad health 
states that are considered as worse than dead are assigned 
negative values. Moreover, the issue is not only that states 
worse than dead may confront researchers with methodologi-
cal problems, but even the fact that people are confronted with 
the notion ‘dead’ may itself introduce all kind of prejudices 
(biases) in their responses. Using the ‘dead’ concept in health 
measurement methods is a contentious issue [107]. The con-
cept of dead is so confrontational and hard to grasp that some 
find it astonishing that health economists make dead a central 
element in their valuation methods [108]. In addition, it seems 
that ‘dead’ cannot be perceived as a manifestation of health 
status as it has a distinct connotation.
Various transformations have been proposed to position 
states that are better or worse than dead on a single metric 
scale. These methods assume that health-state values are 
independent of the duration of the states. However, there 
are some indications that this assumption does not hold, at 
least for severe health states [109–111]. The way variants of 
TTO have been introduced to solve problems regarding valu-
ing states worse than dead is in the absence of a clear analy-
tical framework [112]. Lead-time TTO is an example of 
a seemingly pragmatic solution to a serious methodological 
problem [83].
Furthermore, TTO does not take into account crucial require-
ments in measurement theory such as unidimensionality and 
the invariance principle [90,113–120]. Unidimensionality means 
that there is one dominant, relevant factor or dimension that is 
measured (e.g. valued). To fulfill the principle of invariance, the 
valuation of health states should be: i) independent of the 
group of respondents that performed the valuation task, and 
ii) independent of the set of health states being valued [90,118]. 
Both unidimensionality and invariance seem to be compro-
mised in the TTO method, mainly because it is measuring two 
distinct elements: health status and life years [99]. To achieve 
unidimensionality, measuring only one thing at a time is stan-
dard practice in the natural sciences, such as physics, and it 
amounts to controlling all potential disturbance factors. 
Nunnally and Bernstein [119] put it concisely: ‘a measure should 
generally concern some one thing – some distinct, unitary 
attribute’ (p.4). In regard to the invariance principle, the TTO 
does not seem to be based on this important measurement 
consideration. Another conceptual measurement issue is the 
reference to TTO as a choice method. In fact, TTO could better 
be described as a matching-method. In matching tasks respon-
dents are effectively asked to provide a number that will make 
them indifferent between the options [121,122].
Five years from now, patient-centered measurement will 
become more relevant than the current use of societal values 
of health states, derived by means of TTO or SG. Nowadays, for 
most preference-based instruments values are provided by 
respondents from the general population. The trend is that 
patient’s values will more and more be used [123–126]. ‘If the 
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public at large believes that those who experience health 
states are more reliable informants concerning the value of 
those health states, then the public would presumably choose 
to rely on these informants rather than on its own uninformed 
attitudes.’ [89, p.91]. So, one reason to use patient values is 
that patients are likely to be more adequately informed than 
healthy people. Another reason is that they may be more 
adept at imagining certain health states and thereby be better 
positioned and motivated to make an informed judgment 
about the impact on perceived health of such states, espe-
cially when taking severely impaired health states into account 
[127]. Until now, there have been no convincing ways of 
adapting the TTO method to derive or estimate patients’ 
values, mainly because of ethical issues. For example, using 
the TTO with its time element would imply asking critically ill 
individuals to value the time they might have left. If the 
patient community wants to have a central role in defining 
value, robust processes and other methods than TTO are 
needed to incorporate the patient voice in a form of value 
assessment that is free from adaptation and other biases.
The evolution of other measurement models is ongoing 
[120,128,129]. In research areas other than health economics, 
the evaluation of health is treated most often as an attitude 
[89,120]. Attitudes denote a psychological tendency that is 
expressed by evaluating a particular entity with some degree 
of favor or disfavor [130–132]. One such an alternative method 
to quantify health states may be the discrete choice model 
[25,35]. This choice model is based on (paired) comparisons of 
two or more hypothetical health states. This method has also 
attracted attention by the EuroQol Group (EQ-5D instrument) 
[133]. Another comparison task may offer an attractive alter-
native, namely the multi-attribute profile best-worst task (or 
case 2), one of the three best/worst versions in the Best-Worst 
scaling framework [128]. In the profile task, respondents are 
confronted with one multi-attribute health-state description 
and are asked to indicate the best and the worst attribute 
levels. A drawback of best-worst scaling is that there is not yet 
a uniform statistical procedure to analyze the choice data. 
Another recently introduced patient-centered valuation 
method uses patients’ input on all stages: selection of items 
for the classification system, describing own health condition, 
and assigning a value to their own health condition. This 
system is based on a combination of item response theory 
and discrete choice methods [126,129].
Other methods to measures subjective phenomena, far less 
complicated than the TTO, lack the possibility to produce mea-
sures that are anchored on dead = 0. Therefore, an attractive 
alternative is to combine two methods. Recently, a two-step 
procedure was developed for a preference-based health instru-
ment for infants (Infant Quality of life Instrument: IQI) [134]. 
Coefficients for the levels were obtained from a DCE. These 
coefficients were then normalized using another DCE including 
‘dead’ as a choice option. In this way, the values were rescaled 
from full health (1.0) to dead (0.0). A major benefit of such an 
approach is that the coefficients for the items are based on 
a simple and robust measurement method which will increase 
the reliability and validity of these coefficients. A similar two- 
step approach is proposed for the youth version of the EQ-5D, 
using a composite TTO to normalize the scale from step 1, 
a conventional DCE [135]. Instead of a DCE with dead or time 
elements included, or a TTO to localize the position of dead, 
other methods for step 2 can be considered too [136].
The challenge is to develop inventive methods that overcome 
several shortcomings of the TTO and other conventional meth-
ods. Five years from now, modern software will be more widely 
used, simplifying the complexity of preference-based measure-
ment, and putting the classification and valuation into the hands 
of patients. The full capacity of modern software entails more 
than just simply translations from paper-and-pencil form to an 
electronic mode. Simple to use apps are available, creating con-
venient, attractive tools for patients and researchers. The use of 
such apps in combination of modern measurement models will 
reduce the likelihood that patient responses are biased due to 
adaptation, strategic performance, or other mechanisms.
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